Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective Tumor Embolization plus Axitinib and Ipa-Tuvo in Metastatic Renal Cell Carcinoma
ChiCTR2500105741Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib, iparomlimab and tuvonralimab in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC), sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoint: Objective Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
axitinibiparomlimabtuvonralimab
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on ChiCTR2500105741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105741.